Table 3.

Effect of Topo I Inhibitors on Experimental Liver Metastases of Murine CT-26 Colon Carcinoma When Injected i.p.

Treatment	Liver Metastasis
	Incidence	Liver Weight (g)	Median (range)
Control	9/9	5.00 ± 0.54	58 (45–80)
Control*	5/5	1.56 ± 0.49	9 (5–12)
DB67	9/9	2.55 ± 1.05†,‡	25 (5–55)§
Lipo-DB67	9/9	2.52 ± 1.04†,‡	16 (9–35)§
Irinotecan	9/9	3.45 ± 1.13¶	35 (6–55)§

Balb/C mice were injected in the spleen with 5 x 10⁴ viable CT-26 cells on day 0. Seven days later, mice were splenectomized. On day 14 after cell injection, groups of mice were treated on a schedule of daily infection for 5 days (qdx5/1) with i.p. injections of 7 mg/kg DB67, 7 mg/kg liposomal DB67, or 55 mg/kg irinotecan. Mice were sacrificed on day 21.

Median is the value of the variable that has an equal number of items on either side and divides a frequency distribution into two halves.

^*On day 10 after cell injection.

^†P < .005 as compared to control (vehicle).

^‡P < .05 as compared to irinotecan.

^§P < .001 as compared to control (vehicle).

^¶P < .001 as compared to control (vehicle).